INTRODUCTION
============

Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more of the myeloid lineage cells. With recent expansion of understanding, there has been reclassification of the disease category since the first description of the concept of 'myeloproliferative disorders (MPD)' in the 1950s ([@B1]). A most recent revision of the classification of the diseases in this category has been issued by the World Health Organization (WHO) in 2008 ([@B2]) to include chronic myelogenous leukemia, chronic neutrophilic leukemia, polycythemia vera (PV), primary myelofibrosis (MF), essential thrombocythemia (ET), chronic eosinophilic leukemia, mastocytosis and other unclassifiable MPNs. Of the diseases in the MPN category, the classical Philadelphia chromosome-negative MPNs include PV, MF and ET. Reported worldwide incidence of the classical MPNs combined is approximately 0.5-6/100,000, annually, with peak incidence at the 5th to 7th decades of life ([@B3][@B4][@B5][@B6][@B7][@B8]). However, there have been more recent changes especially regarding accuracy and frequency of the diagnosis of the classical Philadelphia chromosome-negative MPN, owing to the discovery and clinical utilization of mutations in *Janus kinase 2 (JAK2)* ([@B9]) and *Calreticulin (CALR)* ([@B10][@B11]).

The Korean data for the hematologic malignancies ([@B12]) and the myeloid malignancies ([@B13]) have been previously published. During 1999 to 2012, myeloid malignancies took 1.7% of all cancer incidences, and MPNs took 33.8% of the myeloid malignancies. But the incidence and survival for each of disease of the MPN among Korean patients have not been reported.

The Ministry of Health and Welfare, Korea, initiated a nationwide hospital-based cancer registry called the Korea Central Cancer Registry (KCCR) as early as 1980. The registry collected 80%--90% of cancer cases annually from more than 180 training hospitals throughout the country. In 1999, the KCCR expanded cancer registration to cover the entire population under the Population-Based Regional Cancer Registry program. Details of the history, objectives and activities of the KCCR have been documented ([@B14]). Official registration of MPN at KCCR, employing the International Classification of Diseases for Oncology 3rd edition (ICD-O-3) ([@B15]) began in 2003. The Health Insurance Review and Assessment Service (HIRA) of Korea collects the claims data of the National Health Insurance, and offers clinical information including diagnosis, treatment, and prescription data for clinical research. The claims data covered approximately 46 million patients per year which is approximately 90% of the total population in Korea and included claims from almost 80,000 healthcare service providers, as of year 2011 ([@B16]).

The objectives of this report are to estimate and report the nationwide statistics of the classical MPN including PV, MF and ET from 2003 to 2011, using the Korea National Cancer Incidence Data Base (KNCIDB) and HIRA data.

MATERIALS AND METHODS
=====================

Data sources
------------

Incidence data of MPN from year 2003 to 2011 were obtained from the KNCIDB. MPN included the following classification with ICD-O-3 morphology code: PV (M9950/3), MF (M9961/3), and ET (M9962/3). For survival analysis, passive follow-up was performed until 31 December 2012, using mortality database from Statistics Korea.

Number of cases of each diagnosis registered to HIRA of Korea during the same period was also obtained, and the prevalence of each disease was estimated. Drugs (hydroxyurea, interferon-α and danazol) and phlebotomy prescription data, which were available from HIRA for the period between year 2007 and 2011, were gathered to analyze the treatment pattern for the MPN.

Analysis
--------

Crude incidence rates (CR) of each MPN were calculated, by dividing the total number of events by the total number of person-year of observation and multiplying 100,000 to the product. CRs were calculated for total population and also for each sex and age groups. Age-standardized incidence rates (ASR) were defined as weighted average of crude age-specific rates, using the mid-year estimated population of Korea in year 2000 as the standard population. Changes in the annual ASRs of cancer incidence were examined by calculating the annual percentage change over a time period as (exp\[*b*\] -- 1) × 100, where *b* is the slope of the regression of log ASR for a given calendar year ([@B17]).

The survival analysis was done with incidence data registered to KNCIDB and vital status of each patient, followed through December 2012. The survival of each case were determined by the time difference between the date of diagnosis and the date of documented death, censored at the date of loss to follow-up or closing date for follow-up. Relative survival rates were calculated using life table method.

Using the data of number of cases registered to HIRA, we estimated prevalence for each diagnoses. We also used the prescription data for hydroxyurea and phlebotomy, which were available from HIRA. Data on prescription pattern of anagrelide were not available, due to article 9, paragraph 1, No. 7 of the Act on disclosure of public sector information. The patterns of prescription per diagnosis and age groups were analyzed using these data collected from HIRA. All statistical analyses were done with SAS (version 9.2; SAS Institute Inc, Cary, NC, USA).

Ethics statement
----------------

The present study protocol was exempted by the institutional review board of Seoul National University Bundang Hospital (Reg. No. X-1603-340-902).

RESULTS
=======

Incidence
---------

Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most frequent MPN with 2,200 new cases during the period, followed by PV with 1,582 new cases. MF was the least frequent, with 560 new cases. Relative frequencies of MPN per diagnosis in 2011 are depicted in [Fig. 1](#F1){ref-type="fig"}.
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The numbers and the trends of CRs and ASRs from 2003 to 2011 are presented in [Table 1](#T1){ref-type="table"}. The CR of all three diseases in the category combined was 1.40 per 100,000 in 2011, with those of each PV, MF and ET being 0.40/100,000, 0.15/100,000 and 0.84/100,000, respectively. Crude incidence rates of total MPN were higher in men than in women (*P* = 0.005). PV and MF were more frequent in men than in women (*P* \< 0.001 and *P* = 0.004, respectively for PV and MF), and ET was more frequent in women than in men (*P* = 0.004). The ASR of total MPN ranged from 0.45 to 0.94. The annual percentage change of ASR of total MPN was 9.9%, on the increase. The increase in ASR was most significant in ET, with an annual percentage change of 14.6%.

###### Trends in crude incidence rates and age-standardized incidence rates of myeloproliferative neoplasm in Korea by incidence from 2003 to 2011
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  MPN type    Sex             Year   APC                                                        
  ----------- ------- ------- ------ ------ ------ ------ ------ ------ ------ ---------- ----- --
  MPN total   Total   Cases   260    288    406    402    476    538    628    643        701   
  CR          0.54    0.59    0.83   0.82   0.97   1.09   1.26   1.29   1.40                    
  ASR         0.50    0.53    0.73   0.71   0.81   0.89   0.99   0.99   1.05   9.9^\*^          
  Men         Cases   135     152    212    214    261    282    310    337    380              
  CR          0.56    0.63    0.87   0.87   1.06   1.14   1.25   1.35   1.52                    
  ASR         0.55    0.62    0.83   0.82   0.96   1.01   1.07   1.13   1.23   10.0^\*^         
  Women       Cases   125     136    194    188    215    256    318    306    321              
  CR          0.52    0.56    0.80   0.77   0.88   1.04   1.28   1.23   1.28                    
  ASR         0.45    0.47    0.66   0.63   0.67   0.80   0.94   0.87   0.91   9.8^\*^          
  PV          Total   Cases   118    125    165    149    196    178    221    228        202   
  CR          0.24    0.26    0.34   0.30   0.40   0.36   0.45   0.46   0.40                    
  ASR         0.23    0.23    0.30   0.26   0.34   0.30   0.35   0.35   0.31   4.9^\*^          
  Men         Cases   70      77     100    101    131    114    131    138    115              
  CR          0.29    0.32    0.41   0.41   0.53   0.46   0.53   0.55   0.46                    
  ASR         0.28    0.31    0.39   0.38   0.49   0.41   0.45   0.46   0.37   4.6^\*^          
  Women       Cases   48      48     65     48     65     64     90     90     87               
  CR          0.20    0.20    0.27   0.20   0.27   0.26   0.36   0.36   0.35                    
  ASR         0.17    0.16    0.22   0.15   0.20   0.19   0.25   0.23   0.23   4.7^\*^          
  MF          Total   Cases   37     38     53     51     67     77     88     73         76    
  CR          0.08    0.08    0.11   0.10   0.14   0.16   0.18   0.15   0.15                    
  ASR         0.07    0.07    0.09   0.09   0.11   0.12   0.13   0.11   0.11   7.2^\*^          
  Men         Cases   20      23     28     29     34     45     49     47     47               
  CR          0.08    0.09    0.11   0.12   0.14   0.18   0.20   0.19   0.19                    
  ASR         0.08    0.10    0.11   0.11   0.12   0.16   0.16   0.16   0.15   8.5^\*^          
  Women       Cases   17      15     25     22     33     32     39     26     29               
  CR          0.07    0.06    0.10   0.09   0.13   0.13   0.16   0.10   0.12                    
  ASR         0.06    0.05    0.08   0.07   0.10   0.10   0.10   0.08   0.07   4.7              
  ET          Total   Cases   105    125    188    202    213    283    319    342        423   
  CR          0.22    0.26    0.39   0.41   0.43   0.57   0.64   0.69   0.84                    
  ASR         0.20    0.23    0.34   0.36   0.36   0.47   0.51   0.53   0.64   14.6^\*^         
  Men         Cases   45      52     84     84     96     123    130    152    218              
  CR          0.19    0.21    0.34   0.34   0.39   0.50   0.52   0.61   0.87                    
  ASR         0.19    0.22    0.33   0.33   0.35   0.44   0.45   0.51   0.71   15.8^\*^         
  Women       Cases   60      73     104    118    117    160    189    190    205              
  CR          0.25    0.30    0.43   0.48   0.48   0.65   0.76   0.76   0.82                    
  ASR         0.21    0.25    0.36   0.40   0.36   0.51   0.58   0.55   0.60   13.6^\*^         

CR, crude rate; ASR, age-standardized rate; APC, annual percentage change; MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.

^\*^The annual percent change is statistically significantly different from zero (*P* \< 0.05).

Higher incidence of MPN was seen in older age groups, with highest incidence in the age group of 60 to 69 years. ASR on the other hand, showed increasing tendency with increasing age. The ASRs by age groups in 2011 were shown in [Fig. 2](#F2){ref-type="fig"}.

![Age-specific incidence rates of MPN in Korea, 2011. (**A**) Men. (**B**) Women.](jkms-31-1579-g002){#F2}

Survival
--------

Five-year relative survival rates of the patients who were diagnosed with the three diagnosis of MPN from 2003 to 2011 were 89.3%, with lowest relative survival rate in patients with MF (53.1%) and highest relative survival rate in patients with PV (97.7%). The relative survival rate of ET was 92.2%. The relative survival rates of patients with MPN between 2003 and 2011 are summarized in [Table 2](#T2){ref-type="table"}.

###### Relative survival rates with myeloproliferative neoplasm in Korea, 2003-2011
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  Sex     Diseases    No. of cases   Relative survival, %
  ------- ----------- -------------- ----------------------
  Total   MPN total   4,200          89.3
  PV      1,534       97.7           
  MF      533         53.1           
  ET      2,133       92.2           
  Men     MPN total   2,200          88.2
  PV      950         97.9           
  MF      302         48.5           
  ET      948         90.9           
  Women   MPN total   2,000          90.4
  PV      584         97.3           
  MF      231         59.0           
  ET      1,185       93.2           

MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.

Prevalence estimates by cases registered to HIRA
------------------------------------------------

The prevalence data of each diagnosis are summarized in [Table 3](#T3){ref-type="table"}. ET was the most prevalent, and MF the least. The general tendency of prevalence according to diagnosis, sex or age groups were similar to that seen with incidence of KNCIDB data. The total number of cases registered has increased approximately 3.2 fold, during the 9 years of observation from 2003 to 2011.

###### Trends in prevalence of myeloproliferative neoplasm in Korea from 2003 to 2011, estimated with number of cases registered to Health Insurance Review and Assessment Service of Korea

![](jkms-31-1579-i003)

  MPN type    Sex             Year                                                            
  ----------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  MPN total   Total   Cases   2,284   2,737   3,180   3,696   3,942   4,293   4,883   5,295   7,241
  CR          6.04    7.10    7.99    9.10    9.62    9.99    11.03   11.67   12.56           
  ASR         5.48    6.28    6.89    7.70    7.89    7.94    8.46    8.65    9.02            
  Men         Cases   1,216   1,456   1,686   1,932   2,088   2,239   2,546   2,721   3,603   
  CR          4.99    5.92    6.82    7.82    8.37    8.92    10.07   10.82   14.11           
  ASR         4.48    5.22    5.82    6.50    6.75    6.94    7.54    7.78    10.00           
  Women       Cases   1,068   1,281   1,494   1,764   1,854   2,054   2,337   2,574   3,638   
  CR          4.42    5.27    6.11    7.20    7.50    8.25    9.33    10.21   14.34           
  ASR         4.05    4.73    5.34    6.21    6.25    6.70    7.36    7.84    10.84           
  PV          Total   Cases   1,188   1,364   1,516   1,673   1,749   1,824   2,006   2,114   2,304
  CR          2.45    2.79    3.08    3.40    3.52    3.65    3.99    4.18    4.53            
  ASR         2.24    2.48    2.67    2.90    2.91    2.92    3.09    3.15    3.28            
  Men         Cases   688     813     907     1,033   1,096   1,138   1,243   1,285   1,386   
  CR          2.82    3.31    3.67    4.18    4.39    4.53    4.92    5.16    5.43            
  ASR         2.55    2.92    3.16    3.53    3.60    3.61    3.78    3.80    3.91            
  Women       Cases   500     551     609     640     653     686     763     829     918     
  CR          2.07    2.27    2.49    2.61    2.64    2.76    3.05    3.29    3.62            
  ASR         1.88    2.02    2.15    2.23    2.17    2.19    2.34    2.45    2.59            
  MF          Total   Cases   375     488     609     750     851     905     1,065   1,180   1,322
  CR          0.77    1.00    1.24    1.52    1.71    1.81    2.12    2.33    2.60            
  ASR         0.69    0.88    1.06    1.27    1.38    1.41    1.59    1.70    1.83            
  Men         Cases   216     266     317     370     417     442     546     597     659     
  CR          0.89    1.08    1.28    1.50    1.67    1.76    2.16    2.35    2.58            
  ASR         0.78    0.93    1.06    1.20    1.30    1.30    1.53    1.61    1.72            
  Women       Cases   159     222     292     380     434     463     519     583     663     
  CR          0.66    0.91    1.19    1.55    1.76    1.86    2.07    2.31    2.61            
  ASR         0.60    0.82    1.04    1.33    1.45    1.51    1.62    1.77    1.93            
  ET          Total   Cases   721     885     1,055   1,273   1,342   1,564   1,812   2,001   3,615
  CR          1.48    1.81    2.15    2.59    2.70    3.13    3.60    3.96    7.10            
  ASR         1.36    1.60    1.88    2.21    2.24    2.51    2.81    2.99    5.33            
  Men         Cases   312     377     462     529     575     659     757     839     1,558   
  CR          1.28    1.53    1.87    2.14    2.31    2.63    2.99    3.31    6.10            
  ASR         1.15    1.37    1.60    1.77    1.85    2.03    2.23    2.37    4.37            
  Women       Cases   409     508     593     744     767     905     1,055   1,162   2,057   
  CR          1.69    2.09    2.43    3.04    3.10    3.63    4.21    4.61    8.11            
  ASR         1.57    1.89    2.15    2.65    2.63    3.00    3.40    3.62    6.32            

CR, crude rate; ASR, age-standardized rate; MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.

Treatment trends
----------------

Hydroxyurea and phlebotomy prescription data available for years 2007 to 2011 are summarized in [Table 4](#T4){ref-type="table"}. In PV, an average of 61.3% of patients received hydroxyurea, while an average of 39.6% of patients received phlebotomy during the period. In MF, 58.7% received hydroxyurea, and 8.1% phlebotomy; in ET, 61.1% received hydroxyurea and 1.3% phlebotomy. In all diagnoses, the prescription rate of hydroxyurea was higher in older population. However, 20%-40% of patients under 40 years of age were recorded to have been prescribed hydroxyurea ([Fig. 3](#F3){ref-type="fig"}). Over the years, prescription rate for each treatment was kept relatively constant.

###### Trends in prescription of drugs and phlebotomy in myeloproliferative neoplasm (%)
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  MPN type         Sex and age   Prescription   2007          2008   2009   2010   2011   
  ---------------- ------------- -------------- ------------- ------ ------ ------ ------ ------
  PV               Sex           Total          Hydroxyurea   58.6   62.2   61.1   62.2   62.3
  Phlebotomy       39.7          39.3           39.1          40.0   39.9                 
  Men              Hydroxyurea   47.7           51.4          51.1   51.9   52.2          
  Phlebotomy       43.2          43.6           43.6          46.3   44.9                 
  Women            Hydroxyurea   76.9           80.2          61.1   62.2   62.3          
  Phlebotomy       33.7          32.1           31.7          30.0   32.2                 
  Age group, yr    Age \< 40     Hydroxyurea    21.7          28.0   21.6   20.9   20.4   
  Phlebotomy       46.0          44.6           48.9          46.8   52.2                 
  40 ≤ age \< 60   Hydroxyurea   49.6           54.2          52.9   52.2   53.0          
  Phlebotomy       50.2          50.0           47.9          50.4   49.3                 
  Age ≥ 60         Hydroxyurea   74.0           75.1          73.4   75.7   74.3          
  Phlebotomy       29.7          30.3           31.5          32.1   32.1                 
  MF               Sex           Total          Hydroxyurea   54.6   55.0   61.1   59.4   63.6
  Phlebotomy       9.3           7.0            6.6           8.6    9.2                  
  Men              Hydroxyurea   52.0           52.3          51.1   55.6   60.7          
  Phlebotomy       11.5          8.1            7.3           10.4   11.8                 
  Women            Hydroxyurea   57.1           57.7          77.5   63.3   66.5          
  Phlebotomy       7.1           5.8            5.8           6.9    6.5                  
  Age group, yr    Age \< 40     Hydroxyurea    27.8          30.0   35.0   30.4   40.5   
  Phlebotomy       9.7           7.1            7.5           3.8    7.6                  
  40 ≤ age \< 60   Hydroxyurea   47.1           50.2          54.3   57.0   58.0          
  Phlebotomy       14.5          10.9           8.3           12.7   12.7                 
  Age ≥ 60         Hydroxyurea   62             60.2          59.2   63.7   68.4          
  Phlebotomy       6.7           5.2            5.7           7.2    7.6                  
  ET               Sex           Total          Hydroxyurea   60.6   61.7   62.4   63.5   57.5
  Phlebotomy       0.7           1.9            1.3           1.9    0.9                  
  Men              Hydroxyurea   58.8           60.5          62.5   62.9   56.9          
  Phlebotomy       1.2           2.9            2.0           2.9    1.3                  
  Women            Hydroxyurea   61.9           62.5          62.3   63.9   57.9          
  Phlebotomy       0.4           1.1            0.9           1.3    0.6                  
  Age group, yr    Age \< 40     Hydroxyurea    25.1          28.2   31.4   34.7   23.7   
  Phlebotomy       0.6           1.5            1.3           0.4    1.0                  
  40 ≤ age \< 60   Hydroxyurea   55.7           57.5          61.0   61.9   54.8          
  Phlebotomy       0.6           1.8            1.8           2.0    1.4                  
  Age ≥ 60         Hydroxyurea   72.8           72.4          70.3   70.5   67.6          
  Phlebotomy       0.9           1.9            1.0           2.2    0.6                  

MPN, myeloproliferative neoplasm; PV, polycythemia vera; MF, primary myelofibrosis; ET, essential thrombocythemia.

![The proportion of patients with prescription of hydroxyurea and phlebotomy. (**A**) Polycythemia vera. (**B**) Primary myelofibrosis. (**C**) Essential thrombocythemia.](jkms-31-1579-g003){#F3}

DISCUSSION
==========

This is the first study to have presented the epidemiological data of classical, Philadelphia-chromosome negative MPN in Korean patients, utilizing comprehensive data from the KNCIDB and the HIRA. The incidence of all PV, MF, and ET constantly increased during the years observed, with the most recent crude annual incidence of PV, MF, and ET being 0.40, 0.15, and 0.84 per 100,000, respectively. The prevalence rates have also increased over the years, most recent crude rates being 4.53, 2.60, and 7.10 per 100,000 for each PV, MF, and ET, by the HIRA data.

Classical MPNs are rare diseases, but as the disease courses are generally long and as the diseases can cause debilitating symptoms and complications, the optimal diagnosis and management is important in enhancing public health. Current guidelines for diagnosis follow the suggestion published by WHO ([@B18]) and use blood cell counts, bone marrow results and *JAK2* V617F mutation results for diagnosis. More recently, *CALR* mutation was discovered in *JAK2* negative MF and ET patients ([@B10][@B11]), assisting more accurate diagnosis of MPN. Treatment options include low dose aspirin, phlebotomy, and cytoreductive therapy with hydroxyurea, anagrelide, and interferon-α for PV and ET. The classical therapy for MF was bone marrow transplantation. Recently drugs targeting *JAK2* mutation has shown very promising results for classical MPN ([@B19][@B20]).

The epidemiological data of classical MPN reported in other countries were generally in similar range with our data, although variable. A US epidemiological study using the North American Association of Central Cancer Registries (NAACCR) and the Surveillance, Epidemiology, and End Results (SEER) Program data reported incidence rates of PV, MF, and ET at 0.79, 0.25, and 0.53 per 100,000 ([@B7]). HAEMACARE, a European cancer registry-based project to improve the standardization and availability of population-based data on hematologic malignancies, reported crude incidence rate of MPN excluding chronic myeloid leukemia, at 2.24 per 100,000 ([@B8]). A meta-analysis of incidence and prevalence data for classical MPNs published in 2014, suggested the combined annual incidence rates for PV, MF, and ET as 0.84, 0.47, and 1.03 per 100,000, respectively ([@B6]). The meta-analysis report included extensive data of which publication dates ranged from 1946 to 2012. Geographically, the study was intended to include all studies without geographical limits and included one Japanese study, but was analyzed using mostly the US and European data. But even considering the racial and geographical difference, the pooled data showed high heterogeneity, showing heterogeneity in data even from similar geographic regions.

The heterogeneity of data between reports and the constant increasing pattern of incidence/prevalence of our data may be owing to a number of factors. The most important cause is the still growing understanding of the disease, and the development of diagnostic tools and disease classifications, accordingly. WHO classification and diagnostic guidelines for MPN has been re-issued in year 2008, and the discovery of *JAK2* mutation has led to increased recognition of diseases in the MPN category and to more accurate diagnosis. The discovery of *CALR* mutation may even lead to further increase in the number of MPN diagnosis in the future. Another attributable factor is that the systemic registrations of the disease category have only recently begun in many countries. MPN have been officially registered in Korea cancer registry since 2003, and since 2001 in the USA. Other additional factors may include the increase in average life span and improved access to healthcare over the years.

This study is the first to present the Korean nationwide epidemiological data of each disease in the classical MPN category. The statistics are important information for clinicians, researchers as well as administrators, on understanding epidemiological characteristics and establishing future strategies on managing MPNs in Korea. The statistics can be utilized to compare the Korean status to international data and guidelines. Continued systemic registration and periodic report is warranted, to improve the accuracy of the data in association with the improvement in the diagnostic accuracy.
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